不再等待:减少并发症患者的用药等待时间。

IF 1.5 4区 医学 Q3 PSYCHIATRY
Journal of Dual Diagnosis Pub Date : 2022-04-01 Epub Date: 2022-04-07 DOI:10.1080/15504263.2022.2052225
James H Ford, Deepika Rao, Aaron Gilson, Arveen Kaur, Helene Chokron Garneau, Lisa Saldana, Mark P McGovern
{"title":"不再等待:减少并发症患者的用药等待时间。","authors":"James H Ford, Deepika Rao, Aaron Gilson, Arveen Kaur, Helene Chokron Garneau, Lisa Saldana, Mark P McGovern","doi":"10.1080/15504263.2022.2052225","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> Community addiction treatment agencies have utilized Network for the Improvement of Addiction Treatment (NIATx), a proven implementation strategy, to reduce appointment wait-times. However, its effectiveness at reducing medication access wait-times has not been explored. Thus, we conducted an exploratory analysis to evaluate the impact of the NIATx implementation strategies on reduced wait-times to addiction, psychotropic or both medications for individuals with co-occurring disorders (COD). <b>Methods:</b> In a cluster-randomized waitlist control group design, community addiction treatment agencies (<i>n</i> = 49) were randomized to receive the NIATx strategy (Cohort 1, <i>n</i> = 25) or to a Waitlist control (Cohort 2, <i>n</i> = 24). All agencies had a 12-month active intervention period. The primary outcome was the medication encounter wait-time. A univariate general linear model analysis utilizing a logarithmic (log10) transformation examined medication wait-times improvements. <b>Results:</b> The intent-to-treat analysis for psychotropic medications and both medications (reflecting integrated treatment) showed significant main effects for intervention and time, especially comparing Baseline and Year 1 to Year 2. Conversely, only the main effect for time was significant for addiction medications. Wait-time reductions in Cohort 1 agencies was delayed and occurred in the sustainment phase. Wait-times to a psychotropic, addiction, or both medications encounter declined by 3 days, 4.9 days, and 6.8 days, respectively. For Cohort 2 agencies, reduced wait-times were seen for psychotropic (3.4 days), addiction (6 days), and both medications (4.9 days) during their active implementation period. Same- or next-day medication access also improved. <b>Conclusions:</b> NIATx implementation strategies reduced medication encounter wait-times but timing of agency improvements varied. Despite a significant improvement, a three-week wait-time to receive integrated pharmacological interventions is clinically suboptimal for individuals with a COD in need of immediate intervention. Community addiction treatment agencies should identify barriers and implement changes to improve medication access so that their patients \"wait no longer\" to receive integrated treatment and medications for their COD.</p>","PeriodicalId":46571,"journal":{"name":"Journal of Dual Diagnosis","volume":null,"pages":null},"PeriodicalIF":1.5000,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503325/pdf/nihms-1834974.pdf","citationCount":"0","resultStr":"{\"title\":\"Wait No Longer: Reducing Medication Wait-Times for Individuals with Co-Occurring Disorders.\",\"authors\":\"James H Ford, Deepika Rao, Aaron Gilson, Arveen Kaur, Helene Chokron Garneau, Lisa Saldana, Mark P McGovern\",\"doi\":\"10.1080/15504263.2022.2052225\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b>Objective:</b> Community addiction treatment agencies have utilized Network for the Improvement of Addiction Treatment (NIATx), a proven implementation strategy, to reduce appointment wait-times. However, its effectiveness at reducing medication access wait-times has not been explored. Thus, we conducted an exploratory analysis to evaluate the impact of the NIATx implementation strategies on reduced wait-times to addiction, psychotropic or both medications for individuals with co-occurring disorders (COD). <b>Methods:</b> In a cluster-randomized waitlist control group design, community addiction treatment agencies (<i>n</i> = 49) were randomized to receive the NIATx strategy (Cohort 1, <i>n</i> = 25) or to a Waitlist control (Cohort 2, <i>n</i> = 24). All agencies had a 12-month active intervention period. The primary outcome was the medication encounter wait-time. A univariate general linear model analysis utilizing a logarithmic (log10) transformation examined medication wait-times improvements. <b>Results:</b> The intent-to-treat analysis for psychotropic medications and both medications (reflecting integrated treatment) showed significant main effects for intervention and time, especially comparing Baseline and Year 1 to Year 2. Conversely, only the main effect for time was significant for addiction medications. Wait-time reductions in Cohort 1 agencies was delayed and occurred in the sustainment phase. Wait-times to a psychotropic, addiction, or both medications encounter declined by 3 days, 4.9 days, and 6.8 days, respectively. For Cohort 2 agencies, reduced wait-times were seen for psychotropic (3.4 days), addiction (6 days), and both medications (4.9 days) during their active implementation period. Same- or next-day medication access also improved. <b>Conclusions:</b> NIATx implementation strategies reduced medication encounter wait-times but timing of agency improvements varied. Despite a significant improvement, a three-week wait-time to receive integrated pharmacological interventions is clinically suboptimal for individuals with a COD in need of immediate intervention. Community addiction treatment agencies should identify barriers and implement changes to improve medication access so that their patients \\\"wait no longer\\\" to receive integrated treatment and medications for their COD.</p>\",\"PeriodicalId\":46571,\"journal\":{\"name\":\"Journal of Dual Diagnosis\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2022-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503325/pdf/nihms-1834974.pdf\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Dual Diagnosis\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/15504263.2022.2052225\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/4/7 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"PSYCHIATRY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Dual Diagnosis","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/15504263.2022.2052225","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/4/7 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

摘要

目标:社区戒毒机构已利用 "戒毒治疗改进网络"(NIATx)这一行之有效的实施策略来减少预约等候时间。然而,该策略在减少药物获取等待时间方面的有效性尚未得到探讨。因此,我们进行了一项探索性分析,以评估 NIATx 实施策略对减少共存障碍 (COD) 患者的成瘾药物、精神药物或两种药物的等待时间的影响。方法:在分组随机候选对照组设计中,社区戒毒治疗机构(n = 49)被随机分配接受 NIATx 策略(Cohort 1,n = 25)或候选对照组(Cohort 2,n = 24)。所有机构都有 12 个月的积极干预期。主要结果是药物治疗等待时间。利用对数(log10)转换进行的单变量一般线性模型分析考察了用药等待时间的改善情况。结果显示针对精神药物和两种药物(反映综合治疗)的意向治疗分析显示,干预和时间具有显著的主效应,尤其是将基线和第一年与第二年进行比较。相反,对于成瘾药物,只有时间的主效应是显著的。第一组机构等待时间的缩短是延迟的,并且发生在持续阶段。精神药物、成瘾药物或两种药物的等待时间分别缩短了 3 天、4.9 天和 6.8 天。对于第二组机构,在其积极实施期间,精神药物(3.4 天)、成瘾药物(6 天)和两种药物(4.9 天)的等待时间均有所缩短。当日或次日取药的情况也有所改善。结论:NIATx 实施策略缩短了用药等待时间,但机构改善的时间各不相同。尽管情况有了明显改善,但对于需要立即干预的慢性阻塞性肺病患者来说,等待三周才能接受综合药物干预在临床上并不理想。社区戒毒机构应找出障碍并实施变革,以改善药物获取,从而使患者 "不再等待 "接受针对其慢性阻塞性肺病的综合治疗和药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Wait No Longer: Reducing Medication Wait-Times for Individuals with Co-Occurring Disorders.

Objective: Community addiction treatment agencies have utilized Network for the Improvement of Addiction Treatment (NIATx), a proven implementation strategy, to reduce appointment wait-times. However, its effectiveness at reducing medication access wait-times has not been explored. Thus, we conducted an exploratory analysis to evaluate the impact of the NIATx implementation strategies on reduced wait-times to addiction, psychotropic or both medications for individuals with co-occurring disorders (COD). Methods: In a cluster-randomized waitlist control group design, community addiction treatment agencies (n = 49) were randomized to receive the NIATx strategy (Cohort 1, n = 25) or to a Waitlist control (Cohort 2, n = 24). All agencies had a 12-month active intervention period. The primary outcome was the medication encounter wait-time. A univariate general linear model analysis utilizing a logarithmic (log10) transformation examined medication wait-times improvements. Results: The intent-to-treat analysis for psychotropic medications and both medications (reflecting integrated treatment) showed significant main effects for intervention and time, especially comparing Baseline and Year 1 to Year 2. Conversely, only the main effect for time was significant for addiction medications. Wait-time reductions in Cohort 1 agencies was delayed and occurred in the sustainment phase. Wait-times to a psychotropic, addiction, or both medications encounter declined by 3 days, 4.9 days, and 6.8 days, respectively. For Cohort 2 agencies, reduced wait-times were seen for psychotropic (3.4 days), addiction (6 days), and both medications (4.9 days) during their active implementation period. Same- or next-day medication access also improved. Conclusions: NIATx implementation strategies reduced medication encounter wait-times but timing of agency improvements varied. Despite a significant improvement, a three-week wait-time to receive integrated pharmacological interventions is clinically suboptimal for individuals with a COD in need of immediate intervention. Community addiction treatment agencies should identify barriers and implement changes to improve medication access so that their patients "wait no longer" to receive integrated treatment and medications for their COD.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
4.90
自引率
13.60%
发文量
20
期刊介绍: Journal of Dual Diagnosis is a quarterly, international publication that focuses on the full spectrum of complexities regarding dual diagnosis. The co-occurrence of mental health and substance use disorders, or “dual diagnosis,” is one of the quintessential issues in behavioral health. Why do such high rates of co-occurrence exist? What does it tell us about risk profiles? How do these linked disorders affect people, their families, and the communities in which they live? What are the natural paths to recovery? What specific treatments are most helpful and how can new ones be developed? How can we enhance the implementation of evidence-based practices at clinical, administrative, and policy levels? How can we help clients to learn active recovery skills and adopt needed supports, clinicians to master new interventions, programs to implement effective services, and communities to foster healthy adjustment? The Journal addresses each of these perplexing challenges.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信